氯吡格雷与替格瑞洛对维吾尔族ACS患者不同CYP2C19基因代谢型血小板抑制率的比较

目的 比较氯吡格雷与替格瑞洛对维吾尔族急性冠脉综合征(ACS)患者不同CYP2C19基因代谢型血小板抑制率的影响.方法 选取2018年1-8月喀什地区第二人民医院收治的维吾尔族ACS住院患者120例为研究对象,根据治疗方法不同分为观察组(62例)和对照组(58例).对照组采用阿司匹林100 mg/d联合氯吡格雷75 m...

Effects of clopidogrel and ticagrelor on the platelet inhibition rate of different CYP2C19 gene metabolizing type in Uygur ACS

Objective To investigate the effects of clopidogrel and ticagrelor on the platelet inhibition rate of different CYP2C19 gene metabolizing type in Uygur ACS.Methods A total of 120 Uygur ACS hospitalized patients admitted in Kashgar Perfecture Second People's Hospital between January to August 2018 were randomly divided into the control group(58 cases,spirin 100 mg/d combined with clopidogrel 75 mg/d)and the treatment group(62 cases).The treatment group was treated with aspirin 100 mg/d combined with tigrelo 90 mg twice a day.The CYP2C19 genotype was determined by PCR-RFLP method in both groups.The follow-up results of adverse cardiovascular events after 12 months were observed.The platelet inhibition rates of ACS patients in the two groups were compared after treatment with different CYP2C19 genotyping.Platelet inhibition rate and adverse cardiovascular events.Results The incidence of total cardiovascular events in the treatment group was significantly lower than that in the control group(P<0.05),but there was no significant difference between the two groups in inducing major and minor bleeding(P>0.05).The two groups of different CYP2C19 gene polymorphisms were not statistically significant before treatment.After 1 month,6 months,and 12 months of treatment,the platelet inhibition rate of different CYP2C19 gene polymorphisms in the treatment group increased(P<0.05);and treatment The platelet inhibition rate of CYP2C19 gene polymorphism in different groups was significantly higher than that in the control group(P<0.01);the incidence of total cardiovascular events of the three metabolic types in the two groups was significantly higher than that in the control group(P<0.01).There was no significant difference(P>0.05).The incidence of minimal hemorrhage was higher in the middle metabolic group and the slow metabolic group,but there was no significant difference(P>0.05).Conclusion The efficacy of ticagrelor in anti-platelet aggregation in patients with Uygur ACS is not affected by CYP2C19 gene polymorphism.